In addition, several data sets from in vitro studies have also demonstrated that Tα1 treatment helps alleviate lymphopenia in patients with COVID-19 and can promote the proliferation and differentiation of effector T cells, with the potential to regulate immune homoeostasis and cytokine storm in vivo [68,69]. This evidence concerns the gene TAAR1 and COVID-19.